TNSN07069A1 - Process for concentration of antibodies and therapeutic products thereof - Google Patents

Process for concentration of antibodies and therapeutic products thereof

Info

Publication number
TNSN07069A1
TNSN07069A1 TNP2007000069A TNSN07069A TNSN07069A1 TN SN07069 A1 TNSN07069 A1 TN SN07069A1 TN P2007000069 A TNP2007000069 A TN P2007000069A TN SN07069 A TNSN07069 A TN SN07069A TN SN07069 A1 TNSN07069 A1 TN SN07069A1
Authority
TN
Tunisia
Prior art keywords
antibodies
concentration
therapeutic products
ultrafiltering
highly concentrated
Prior art date
Application number
TNP2007000069A
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of TNSN07069A1 publication Critical patent/TNSN07069A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
TNP2007000069A 2004-09-09 2007-02-23 Process for concentration of antibodies and therapeutic products thereof TNSN07069A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
TNSN07069A1 true TNSN07069A1 (en) 2008-06-02

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000069A TNSN07069A1 (en) 2004-09-09 2007-02-23 Process for concentration of antibodies and therapeutic products thereof

Country Status (32)

Country Link
US (6) US20060051347A1 (cg-RX-API-DMAC7.html)
EP (5) EP2292636B9 (cg-RX-API-DMAC7.html)
JP (2) JP5210633B2 (cg-RX-API-DMAC7.html)
KR (2) KR20070109975A (cg-RX-API-DMAC7.html)
CN (3) CN101056885B (cg-RX-API-DMAC7.html)
AR (1) AR050641A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005285243C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0515649B8 (cg-RX-API-DMAC7.html)
CA (1) CA2577317C (cg-RX-API-DMAC7.html)
DK (5) DK3805248T5 (cg-RX-API-DMAC7.html)
EC (1) ECSP077282A (cg-RX-API-DMAC7.html)
ES (5) ES2968070T3 (cg-RX-API-DMAC7.html)
FI (4) FI4108259T3 (cg-RX-API-DMAC7.html)
GT (1) GT200500254A (cg-RX-API-DMAC7.html)
HU (4) HUE061899T2 (cg-RX-API-DMAC7.html)
IL (2) IL181372A (cg-RX-API-DMAC7.html)
LT (4) LT4108259T (cg-RX-API-DMAC7.html)
MA (1) MA28991B1 (cg-RX-API-DMAC7.html)
MX (2) MX2007002812A (cg-RX-API-DMAC7.html)
MY (2) MY150549A (cg-RX-API-DMAC7.html)
NO (1) NO333660B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ553239A (cg-RX-API-DMAC7.html)
PE (1) PE20060816A1 (cg-RX-API-DMAC7.html)
PL (5) PL2292636T3 (cg-RX-API-DMAC7.html)
PT (5) PT2292636T (cg-RX-API-DMAC7.html)
RU (1) RU2390524C2 (cg-RX-API-DMAC7.html)
SG (1) SG177161A1 (cg-RX-API-DMAC7.html)
SI (5) SI4104859T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07069A1 (cg-RX-API-DMAC7.html)
TW (1) TWI372630B (cg-RX-API-DMAC7.html)
WO (1) WO2006031560A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701626B (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
PT1765294E (pt) 2004-05-12 2008-12-30 Baxter Healthcare Sa Microesferas de ácido nucleico, sua produção e entrega
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
EP2583744A1 (en) * 2006-03-31 2013-04-24 Genencor International, Inc. Permeate product of tangential flow filtration process
BRPI0709737A2 (pt) 2006-04-04 2011-07-26 Zymenex As processo para concentraÇço de um polipeptÍdeo
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR101215740B1 (ko) * 2007-07-17 2012-12-27 루드비히-막시밀리안스-우니버지테트 뮌헨 가변적 접선류 여과
JP5205470B2 (ja) * 2007-11-29 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリン凝集物
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TW200938221A (en) * 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
AU2009236305B2 (en) * 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
RU2010151414A (ru) * 2008-05-15 2012-06-20 В.Хэлт Л.П. (Bs) Способ получения фракций молока, обогащенных секреторными иммуноглобулинами
CA2744510A1 (en) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
SI2483304T1 (sl) * 2009-09-29 2016-08-31 F. Hoffmann-La Roche Ag Predfiltracijsko naravnavanje pufrskih snovi za močno koncentriran imunoglobulinski pripravek
ES2604103T3 (es) * 2009-10-01 2017-03-03 F. Hoffmann-La Roche Ag Filtración final de una preparación de inmunoglobulina en múltiples pasos
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
PH12012501742A1 (en) 2010-03-01 2022-03-21 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US20150361131A1 (en) * 2012-12-28 2015-12-17 Novo Nordisk A/S High temperature dead end antibody filtration
JP6427502B2 (ja) 2013-01-09 2018-11-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａの精製方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
IL296603B2 (en) 2014-05-13 2024-04-01 Amgen Inc Process control systems and methods for use with filters and filtration processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
US10550148B2 (en) * 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
KR102199262B1 (ko) 2014-06-25 2021-01-06 이엠디 밀리포어 코포레이션 밀집한 나권형 필터 엘리먼트, 모듈 및 시스템
KR102235952B1 (ko) 2014-08-29 2021-04-07 이엠디 밀리포어 코포레이션 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
CN105592913B (zh) 2014-08-29 2018-04-03 Emd 密理博公司 用于使用单程切向流过滤系统和具有渗余物的再循环的切向流过滤系统过滤液体的方法
BR112017008125B1 (pt) 2014-10-23 2023-11-21 Amgen Inc. Método para a redução da viscosidade de formulações farmacêuticas, formulações farmacêuticas, método de preparação de um pó liofilizado, pó liofilizado e método para reconstituição de um pó liofilizado
WO2016087569A1 (en) 2014-12-03 2016-06-09 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20180037056A (ko) * 2015-09-22 2018-04-10 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
CA3023486C (en) 2016-06-09 2022-03-29 Emd Millipore Corporation Radial-path filter elements, systems and methods of using same
SG11201901220XA (en) * 2016-08-16 2019-03-28 Genzyme Corp Methods of processing a fluid including a recombinant therapeutic protein and use thereof
SG11201901081XA (en) * 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
KR102754228B1 (ko) * 2017-12-27 2025-01-14 (주)셀트리온 투석 여과 방법
EP3774894A1 (en) * 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
TWI846694B (zh) 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
MA53272A (fr) * 2018-08-10 2021-11-17 Amgen Inc Procédé de préparation d'une formulation pharmaceutique d'anticorps
EP3837273B1 (en) * 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
AU2020223376A1 (en) * 2019-02-15 2021-07-22 Just - Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
EP3791395B1 (en) * 2019-07-31 2021-08-11 Catalent U.K. Swindon Zydis Limited Density flow meter for pharmaceutical formulation dosing
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
KR20230080460A (ko) * 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
CA3199735A1 (en) 2020-11-23 2022-05-27 Chris Klopp Filtration systems,components and methods
EP4304764A1 (en) * 2021-03-08 2024-01-17 Boehringer Ingelheim International GmbH Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
EP4482956A1 (en) 2022-02-25 2025-01-01 Amgen Inc. Methods of preparing high concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
CA3261698A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh METHODS FOR PREPARING A HIGHLY CONCENTRATED PD1 ANTIBODY SOLUTION BY ULTRAFILTRATION/DIAFILTRATION (UF/DF)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
WO2024224337A1 (en) * 2023-04-25 2024-10-31 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (cg-RX-API-DMAC7.html) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (cg-RX-API-DMAC7.html) * 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH04502914A (ja) 1988-12-15 1992-05-28 セントユール，インコーポレイテッド 免疫グロブリンを可溶化するための塩基性アミノ酸の使用
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
KR20010030665A (ko) 1997-09-22 2001-04-16 세프라겐 코포레이션 유장 단백질의 순차적 분리법 및 그의 제제
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001003515A1 (en) 1999-07-07 2001-01-18 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
CA2477857C (en) 1999-10-04 2012-04-10 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
WO2003042344A2 (en) * 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
JP4500683B2 (ja) * 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CA2516836A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
US8471757B2 (en) 2004-08-19 2013-06-25 Electronic Navigation Research Institute, An Independent Administrative Institution Device using dielectric lens
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Also Published As

Publication number Publication date
ES2968070T3 (es) 2024-05-07
FI3805248T3 (fi) 2023-04-21
SI4104859T1 (sl) 2024-08-30
NO333660B1 (no) 2013-08-05
LT4104859T (lt) 2024-07-10
AR050641A1 (es) 2006-11-08
EP1786830A2 (en) 2007-05-23
JP2008512473A (ja) 2008-04-24
SI1786830T1 (sl) 2015-03-31
SG177161A1 (en) 2012-01-30
US20070237762A1 (en) 2007-10-11
AU2005285243A1 (en) 2006-03-23
EP1786830B1 (en) 2014-11-12
HK1101249A1 (en) 2007-10-12
FI2292636T3 (fi) 2024-01-12
US20140370003A1 (en) 2014-12-18
SI3805248T1 (sl) 2023-05-31
ES2975166T3 (es) 2024-07-03
US10370456B2 (en) 2019-08-06
IL181372A0 (en) 2007-07-04
PL1786830T3 (pl) 2015-05-29
ES2942574T3 (es) 2023-06-02
EP4108259B1 (en) 2024-01-03
CN104961797A (zh) 2015-10-07
MY162525A (en) 2017-06-15
US12371510B2 (en) 2025-07-29
JP2012097086A (ja) 2012-05-24
BRPI0515649B8 (pt) 2021-11-03
PT3805248T (pt) 2023-04-05
KR101528970B1 (ko) 2015-06-15
ES2528541T3 (es) 2015-02-10
KR20070109975A (ko) 2007-11-15
DK3805248T5 (da) 2023-04-24
US20060051347A1 (en) 2006-03-09
AU2005285243C1 (en) 2012-10-25
CN104961797B (zh) 2020-12-25
EP3805248B1 (en) 2023-01-18
KR20120135530A (ko) 2012-12-14
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
FI4108259T3 (fi) 2024-09-10
SI2292636T1 (sl) 2024-02-29
NO20071432L (no) 2007-03-16
PE20060816A1 (es) 2006-09-02
NZ553239A (en) 2009-11-27
EP4108259A1 (en) 2022-12-28
AU2005285243B2 (en) 2012-03-08
ECSP077282A (es) 2007-03-29
WO2006031560A2 (en) 2006-03-23
ZA200701626B (en) 2008-10-29
US20090214522A1 (en) 2009-08-27
PT4104859T (pt) 2024-07-02
US11767370B2 (en) 2023-09-26
PL4104859T3 (pl) 2024-08-26
EP2292636A2 (en) 2011-03-09
CA2577317A1 (en) 2006-03-23
TW200612989A (en) 2006-05-01
BRPI0515649A (pt) 2008-07-29
DK1786830T3 (en) 2015-01-19
HUE061899T2 (hu) 2023-08-28
EP2292636B1 (en) 2023-10-18
TWI372630B (en) 2012-09-21
WO2006031560A3 (en) 2006-08-24
LT4108259T (lt) 2024-04-10
CN101056885B (zh) 2015-08-26
FI4104859T3 (fi) 2024-07-16
CN101056885A (zh) 2007-10-17
LT3805248T (lt) 2023-04-25
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
MX2007002812A (es) 2007-05-16
DK4104859T3 (da) 2024-07-08
DK4108259T3 (da) 2024-03-11
MX342788B (es) 2016-10-12
CN102911268A (zh) 2013-02-06
EP2292636B9 (en) 2024-01-03
PL3805248T3 (pl) 2023-05-22
IL181372A (en) 2012-01-31
JP5426641B2 (ja) 2014-02-26
HUE067662T2 (hu) 2024-11-28
KR101528970B9 (ko) 2022-12-09
PL4108259T3 (pl) 2024-05-13
IL216851A0 (en) 2012-01-31
HK1215869A1 (zh) 2016-09-23
MY150549A (en) 2014-01-30
CA2577317C (en) 2016-04-26
PT1786830E (pt) 2015-02-05
ES2983099T3 (es) 2024-10-22
BRPI0515649B1 (pt) 2021-10-13
SI4108259T1 (sl) 2024-04-30
DK3805248T3 (da) 2023-04-03
HUE067296T2 (hu) 2024-10-28
JP5210633B2 (ja) 2013-06-12
PT4108259T (pt) 2024-03-07
EP4104859A1 (en) 2022-12-21
EP2292636A3 (en) 2013-05-01
HUE065025T2 (hu) 2024-04-28
PL2292636T3 (pl) 2024-03-11
US20230074486A1 (en) 2023-03-09
EP3805248A3 (en) 2021-07-14
DK2292636T3 (da) 2024-01-15
RU2390524C2 (ru) 2010-05-27
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
EP4104859B1 (en) 2024-04-17
MA28991B1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
TNSN07069A1 (en) Process for concentration of antibodies and therapeutic products thereof
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2005063820A3 (en) Il-7 fusion proteins
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
AU2003215188A8 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2004065417A3 (en) Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
NO20072473L (no) Fremgangsmate for fremstilling av kinolinforbindelser og oppnadde produkter
WO2003074004A3 (en) Method of producing antigens
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
JOP20050124B1 (ar) عملية تركيز الاجسام المضادة والمنتجات العلاجية منها
EP1964847A3 (en) Method and apparatus for continuous large-scale radiolabeling of proteins
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
WO2001004143A3 (en) Prostase vaccine
CY1115969T1 (el) Διαδικασια για συμπυκνωση αντισωματων και θεραπευτικων προϊοντων αυτων
WO2005092922A3 (de) Antigen des pm-2 antikörpers und dessen verwendung